The short interest data are out for the most recent settlement date, August 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside.
As we have said before, FDA rulings can make or break the biotech stocks, and short sellers and mega-bulls often go to war against each other in these companies. After all, if a single failed clinical trial can mean disaster for a stock, then some short sellers can argue for a stock implosion down the road.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The August 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.78 million shares from the previous level of 9.98 million. Shares were last seen trading at $196.64, in a 52-week trading range of $163.31 to $201.23.
Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 3.35 million shares from the previous 4.00 million. The stock recently traded at $342.33, within a 52-week range of $249.17 to $388.67.
Celgene Corp.’s (NASDAQ: CELG) short interest for this settlement date increased to 15.81 million shares from the previous level of 15.39 million. Shares were changing hands at $89.93, in a 52-week trading range of $74.13 to $147.17.
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest decrease to 13.98 million shares from 14.41 million in the previous period. Shares were trading at $73.59, in a 52-week range of $64.27 to $89.54.
The number of MannKind Corp. (NASDAQ: MNKD) shares short decreased to 28.61 million. The previous reading was 30.15 million. The stock was last seen at $1.12 a share, in a 52-week range of $0.98 to $6.96.
Alexion Pharmaceuticals Inc.’s (NASDAQ: ALXN) short interest fell to 3.60 million shares from the previous 4.46 million. Shares were trading at $117.50, in a 52-week range of $102.10 to $149.34.
24/7 Wall St.Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
